Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Women's health is in fact a direct reflection of the nation's overall health
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
The facility is spread across 215000 sq. feet and provides super-speciality care
New biotechnology product aims to be world's fastest automatic sanitary solution
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Subscribe To Our Newsletter & Stay Updated
